by rss feed | Apr 16, 2023 | biotechs, Exondys 51, News Feeds, Sarepta, SRP-9001, weekly reads
The biotech Sarepta has had a complicated go of it with the FDA sometimes related to their Duchenne muscular dystrophy (DMD) gene therapy efforts. In late 2016 I wrote about how there was some controversy as the FDA approved the Sarepta drug eteplirsen (Exondys 51)...
